

# George Therapondos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5321556/george-therapondos-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

2,980

citations

29

h-index

54

g-index

72

ext. papers

3,438

ext. citations

4.9

avg, IF

4.76

L-index

#	Paper	IF	Citations
63	Low Rates of Hepatitis B Virus Treatment Among Treatment-Eligible Patients in Safety-Net Health Systems. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> ,	3	2
62	Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. <i>Liver Transplantation</i> , <b>2021</b> , 27, 548-557	4.5	9
61	The Utilization and Diagnostic Yield of Upper Endoscopy for Evaluation of Gastrointestinal Symptoms Within the First Year After Liver Transplantation. <i>Cureus</i> , <b>2020</b> , 12, e11323	1.2	
60	Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	3
59	Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. <i>Nature Reviews Nephrology</i> , <b>2020</b> , 16, 137-155	14.9	37
58	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 816-827	13.4	88
57	Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database. <i>Liver Transplantation</i> , <b>2019</b> , 25, 706-711	4.5	15
56	Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?. <i>Hepatology</i> , <b>2019</b> , 69, 51-63	11.2	28
55	Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. <i>Gastroenterology</i> , <b>2019</b> , 157, 472-480.e5	13.3	25
54	Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score. <i>Hepatology</i> , <b>2019</b> , 69, 1477-1487	11.2	54
53	Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , <b>2018</b> , 155, 422-430.e1	13.3	155
52	Point Shear Wave Elastography in Assessment of Hepatic Fibrosis: Diagnostic Accuracy in Subjects With Native and Transplanted Livers Referred for Percutaneous Biopsy. <i>Ultrasound Quarterly</i> , <b>2016</b> , 32, 201-7	1.4	11
51	Sa1626 Transcatheter Aortic Valve Replacement (TAVR) for Severe Aortic Stenosis as a Bridge to Liver Transplantation. <i>Gastroenterology</i> , <b>2016</b> , 150, S1080	13.3	2
50	Health-related quality of life in long-term survivors of paediatric liver transplantation. <i>Paediatrics and Child Health</i> , <b>2015</b> , 20, 189-94	0.7	11
49	"Weighing the risk": Obesity and outcomes following liver transplantation. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1484-93	3.4	13
48	A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. <i>Journal of the Academy of Nutrition and Dietetics</i> , <b>2014</b> , 114, 1181-94	3.9	60
47	One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 28, 41-4	2.8	28

46	Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. <i>International Journal of Experimental Pathology</i> , <b>2014</b> , 95, 209-15	2.8	19
45	The impact of obesity as determined by modified body mass index on long-term outcome after liver transplantation: Canadian single-center experience. <i>Transplantation Proceedings</i> , <b>2013</b> , 45, 2288-94 <sup>1.1</sup>		25
44	Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. <i>Transplant International</i> , <b>2013</b> , 26, 42-9	3	14
43	Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. <i>Applied Physiology, Nutrition and Metabolism</i> , <b>2013</b> , 38, 334-40	3	75
42	Excellent liver retransplantation outcomes in hepatitis C-infected recipients. <i>Clinical Transplantation</i> , <b>2013</b> , 27, E512-20	3.8	1
41	Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. <i>Liver Transplantation</i> , <b>2013</b> , 19, 611-8	4.5	29
40	Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, 131-6		1
39	The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. <i>Clinical Transplantation</i> , <b>2012</b> , 26, E561-9	3.8	16
38	Health state utilities and quality of life in patients with hepatitis B. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 445-51		40
37	Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. <i>Liver International</i> , <b>2012</b> , 32, 510-8	7.9	30
36	Tolerance to liver allograft after allogeneic hematopoietic cell transplantation for severe aplastic anemia from the same HLA-matched sibling donor. <i>Bone Marrow Transplantation</i> , <b>2012</b> , 47, 1128-30	4.4	2
35	Liver transplantation at the Ochsner Clinic: programmatic expansion and outcomes improvement. <i>Clinical Transplants</i> , <b>2012</b> , 111-20		1
34	Oxidative stress and nutritional factors in hepatitis C virus-positive liver recipients, controls, and hepatitis C virus-positive nontransplant patients. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 1744-9	1.1	4
33	Cosmesis and body image after adult right lobe living liver donation. <i>Transplantation</i> , <b>2010</b> , 89, 1270-5	1.8	18
32	Adult living liver donors have excellent long-term medical outcomes: the University of Toronto liver transplant experience. <i>American Journal of Transplantation</i> , <b>2010</b> , 10, 364-71	8.7	76
31	Adult right-lobe living liver donors: quality of life, attitudes and predictors of donor outcomes. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 1169-78	8.7	77
30	Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. <i>Hepatology</i> , <b>2009</b> , 50, 825-33	11.2	180
29	Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1288-95	4.5	50

28	Financial, vocational, and interpersonal impact of living liver donation. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1435-42	4.5	13
27	A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1776-82	4.5	78
26	Hepatic lipid peroxidation and antioxidant micronutrients in hepatitis virus C liver recipients with and without disease recurrence. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 3800-5	1.1	8
25	Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. <i>Transplantation</i> , <b>2009</b> , 88, 1214-21	1.8	106
24	Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. <i>Liver Transplantation</i> , <b>2008</b> , 14, 651-9	4.5	51
23	The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. <i>Liver Transplantation</i> , <b>2008</b> , 14, 1778-86	4.5	60
22	The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. <i>Hepatology</i> , <b>2006</b> , 44, 640-9	11.2	4
21	Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. <i>Gut</i> , <b>2006</b> , 55, 1290-5	19.2	30
20	Miscellaneous indications for transjugular intrahepatic portosystemic stent-shunt. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2006</b> , 18, 1161-6	2.2	6
19	Review article: recent advances in the management of bleeding gastric varices. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 1-17	6.1	42
18	The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2005</b> , 17, 1379-85	2.2	48
17	Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2004</b> , 99, 390-4	0.7	27
16	Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2004</b> , 19, 73-7	4	25
15	Cardiac morbidity and mortality related to orthotopic liver transplantation. <i>Liver Transplantation</i> , <b>2004</b> , 10, 1441-53	4.5	656
14	185 The effects of losartan, an angiotensin II receptor antagonist, on posture related sodium handling in ascites-free post-tips cirrhotic patients previously treated for refractory ascites. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 60	13.4	84
13	Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both?. <i>Transplantation</i> , <b>2003</b> , 76, 446-7; author reply 447-8	1.8	1
12	Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. <i>Clinical Science</i> , <b>2003</b> , 105, 1-8	6.5	43
11	A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. <i>Biomedical Chromatography</i> , <b>2002</b> , 16, 365-72	1.7	36

10	Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 373-80	6.1	51
9	Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. <i>Liver Transplantation</i> , <b>2002</b> , 8, 690-700	4.5	59
8	The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. <i>Gut</i> , <b>2002</b> , 51, 270-4	19.2	160
7	Transjugular intrahepatic portosystemic stent-shunt and its effects on orthotopic liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 827-32	2.2	45
6	Management of gastro-oesophageal varices. <i>Clinical Medicine</i> , <b>2002</b> , 2, 297-302	1.9	1
5	The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection. <i>Transplantation</i> , <b>2000</b> , 69, 1514-7	1.8	82
4	Health effects of alcohol and alcoholism. <i>Clinics in Dermatology</i> , <b>1999</b> , 17, 381-9	3	4
3	Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 479-84	13.4	55
2	Role of reactive oxygen intermediates (ROI) in the myocardial injury of liver cirrhosis. <i>Gastroenterology</i> , <b>1998</b> , 114, A1354	13.3	2
1	Infections in the Liver202-211		